#ACC22 [Not published yet] – RCT: Mavacamten reduces the need for surgical intervention in patients with obstructive hypertrophic cardiomyopathy.
4 Apr, 2022 | 01:13h | UTCCommentaries:
Mavacamten Slashes Need for Septal Reduction in Obstructive HCM: VALOR-HCM – TCTMD
Commentary on Twitter
ICYMI: The VALOR-HCM trial at #ACC22 showed that mavacamten improved symptoms & significantly reduced eligibility for needing septal reduction therapy (SRT) among symptomatic patients with obstructive #cvHCM. Check out the Trial Summary here: https://t.co/fXVp8H0bw5 @DLBHATTMD pic.twitter.com/f0gPp9dNX8
— American College of Cardiology (@ACCinTouch) April 2, 2022